Asimina Mataftsi1, Stella Moutzouri2, Paraskevi Karagianni3, Nikolaos Ziakas2, Vasiliki Soubasi3, Periklis Brazitikos2, Anna-Bettina Haidich4. 1. 2nd Department of Ophthalmology, Medical School, Aristotle University of Thessaloniki, "Papageorgiou" Hospital, 56429, N.Efkarpia, Thessaloniki, Greece. amatafts@auth.gr. 2. 2nd Department of Ophthalmology, Medical School, Aristotle University of Thessaloniki, "Papageorgiou" Hospital, 56429, N.Efkarpia, Thessaloniki, Greece. 3. 2nd Department of Neonatal Care Unit, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece. 4. Department of Hygiene and Epidemiology, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Abstract
PURPOSE: To assess the frequency of retinopathy of prematurity (ROP) and evaluate the appropriateness of screening guidelines in a tertiary hospital in Thessaloniki, Greece. METHODS: Retrospective review of consecutive infants admitted to the IInd Department of the Neonatal Care Unit of Aristotle University in the period April 2004-2015. ROP screening took place according to the Royal College of Paediatrics and Child Health and Royal College of Ophthalmologists (UK) guidelines [i.e. gestational age < 32 weeks and/or birth weight < 1501 g)], plus a few additional cases due to comorbidity. RESULTS: 1178 out of the 8782 admitted infants underwent ROP screening. ROP was detected in 232 (19.7%) infants of whom 87 developed severe form of the disease (i.e. ≥ stage 3). Treatment was required in 30 (2.5%) infants, all of whom fulfilled the screening criteria. Two of the 206 infants who were additionally screened due to comorbidity developed severe ROP which regressed spontaneously. Disease regression was achieved in 27/29 (93%) treated infants who survived. CONCLUSIONS: The frequency of ROP observed in this cohort was as low as that reported in other developed countries. The currently used screening criteria permitted identification of all infants who were at risk and, therefore, need not be changed.
PURPOSE: To assess the frequency of retinopathy of prematurity (ROP) and evaluate the appropriateness of screening guidelines in a tertiary hospital in Thessaloniki, Greece. METHODS: Retrospective review of consecutive infants admitted to the IInd Department of the Neonatal Care Unit of Aristotle University in the period April 2004-2015. ROP screening took place according to the Royal College of Paediatrics and Child Health and Royal College of Ophthalmologists (UK) guidelines [i.e. gestational age < 32 weeks and/or birth weight < 1501 g)], plus a few additional cases due to comorbidity. RESULTS: 1178 out of the 8782 admitted infants underwent ROP screening. ROP was detected in 232 (19.7%) infants of whom 87 developed severe form of the disease (i.e. ≥ stage 3). Treatment was required in 30 (2.5%) infants, all of whom fulfilled the screening criteria. Two of the 206 infants who were additionally screened due to comorbidity developed severe ROP which regressed spontaneously. Disease regression was achieved in 27/29 (93%) treated infants who survived. CONCLUSIONS: The frequency of ROP observed in this cohort was as low as that reported in other developed countries. The currently used screening criteria permitted identification of all infants who were at risk and, therefore, need not be changed.
Entities:
Keywords:
Epidemiology; Paediatric ophthalmology; Prematurity; Retinopathy of prematurity; Screening
Authors: N G Ziakas; D G Cottrell; D W Milligan; P M Pennefather; M A Bamashmus; M P Clarke Journal: Br J Ophthalmol Date: 2001-07 Impact factor: 4.638
Authors: Ana Catalina Tabarez-Carvajal; Milagro Montes-Cantillo; Kelly H Unkrich; Rupal H Trivedi; Mae Millicent Winfrey Peterseim Journal: Br J Ophthalmol Date: 2017-04-12 Impact factor: 4.638
Authors: Cassie A Ludwig; Tiffany A Chen; Tina Hernandez-Boussard; Andrew A Moshfeghi; Darius M Moshfeghi Journal: Ophthalmic Surg Lasers Imaging Retina Date: 2017-07-01 Impact factor: 1.300
Authors: I C Asproudis; S K Andronikou; E A Hotoura; C D Kalogeropoulos; G K Kitsos; K E Psilas Journal: Eur J Ophthalmol Date: 2002 Nov-Dec Impact factor: 2.597